Advertisement

Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging

  • Naoki Ezawa
  • Nagaaki Katoh
  • Kazuhiro Oguchi
  • Tsuneaki Yoshinaga
  • Masahide Yazaki
  • Yoshiki Sekijima
Original Article

Abstract

Purpose

To investigate the utility of Pittsburgh compound B (PiB) positron emission tomography (PET) imaging for evaluating whole-body amyloid involvement in patients with systemic amyloidosis.

Methods

Whole-body 11C-PiB PET was performed in seven patients with systemic immunoglobulin light-chain (AL) amyloidosis, seven patients with hereditary transthyretin (ATTRm) amyloidosis, one asymptomatic TTR mutation carrier and three healthy controls. The correlations between clinical organ involvement, radiological 11C-PiB uptake and histopathological findings were analysed for each organ.

Results

Organ involvement on 11C-PiB PET imaging showed good correlations with the clinical findings for the heart and stomach. Abnormal tracer uptake was also observed in the spleen, lachrymal gland, submandibular gland, sublingual gland, lymph node, brain, scalp, extraocular muscles, nasal mucosa, pharynx, tongue and nuchal muscles, most of which were asymptomatic. Physiological tracer uptake was universally observed in the urinary tract (kidney, renal pelvis, ureter and bladder) and enterohepatic circulatory system (liver, gallbladder, bile duct and small intestine) in all participants. Most of the patients and one healthy control subject showed asymptomatic tracer uptake in the lung and parotid gland. The peripheral nervous system did not show any tracer uptake even in patients with apparent peripheral neuropathy. Histological amyloid deposition was confirmed in biopsied myocardium and gastric mucosa where abnormal 11C-PiB retention was observed.

Conclusions

11C-PiB PET imaging can be used clinically in the systemic evaluation of amyloid distribution in patients with AL and ATTRm amyloidosis. Quantitative analysis of 11C-PiB PET images may be useful in therapy evaluation and will reveal whether amyloid clearance is correlated with clinical response.

Keywords

Amyloid Pittsburgh compound B PET Amyloid imaging Light-chain amyloidosis Hereditary transthyretin amyloidosis 

Notes

Funding

This study was funded by a Grant-in-aid for Scientific Research (C) (23,591,237 to Y.S.) from the Japan Society for the Promotion of Science, a grant from the Amyloidosis Research Committee, the Ministry of Health, Labour and Welfare, Japan, and 2015 Global ASPIRE TTR-FAP Competitive Research Grant Award from Pfizer, Inc.

Compliance with ethical standards

Conflicts of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14.  https://doi.org/10.1007/s00259-012-2237-2.CrossRefPubMedGoogle Scholar
  2. 2.
    Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–34.  https://doi.org/10.1002/ana.21164.CrossRefPubMedGoogle Scholar
  3. 3.
    LeVine H III. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20.  https://doi.org/10.2967/jnumed.111.102053.CrossRefPubMedGoogle Scholar
  5. 5.
    Hellstrom-Lindahl E, Westermark P, Antoni G, Estrada S. In vitro binding of [3H]PIB to human amyloid deposits of different types. Amyloid. 2014;21:21–7.  https://doi.org/10.3109/13506129.2013.860895.CrossRefPubMedGoogle Scholar
  6. 6.
    Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–81.  https://doi.org/10.1212/wnl.0000000000003001.CrossRefPubMedGoogle Scholar
  7. 7.
    Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004, 18-22 April 2004. Am J Hematol. 2005;79:319–28.  https://doi.org/10.1002/ajh.20381.
  8. 8.
    Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785–91.  https://doi.org/10.1016/j.humpath.2011.03.004.CrossRefPubMedGoogle Scholar
  9. 9.
    Scheinin NM, Tolvanen TK, Wilson IA, Arponen EM, Nagren KA, Rinne JO. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med. 2007;48:128–33.PubMedGoogle Scholar
  10. 10.
    Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508–13.  https://doi.org/10.1056/nejm199008233230803.CrossRefPubMedGoogle Scholar
  11. 11.
    Rydh A, Suhr O, Hietala SO, Ahlstrom KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, et al. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet. 1991;338:335–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol. 2011;179:1978–87.  https://doi.org/10.1016/j.ajpath.2011.06.024.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hutt DF, Gilbertson J, Quigley AM, Wechalekar AD. (99m)Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis. Amyloid. 2016;23:134–5.  https://doi.org/10.3109/13506129.2016.1158160.CrossRefPubMedGoogle Scholar
  15. 15.
    Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29:376–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Quarta CC, Obici L, Guidalotti PL, Pieroni M, Longhi S, Perlini S, et al. High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid. 2013;20:48–51.  https://doi.org/10.3109/13506129.2012.746938.CrossRefPubMedGoogle Scholar
  17. 17.
    Rao BK, Padmalatha C, Au Buchon J, Lieberman LM. Hepatic and splenic scintigraphy in idiopathic systemic amyloidosis. Eur J Nucl Med. 1981;6:143–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990;16:663–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.  https://doi.org/10.1161/circimaging.112.000132.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23:58–63.  https://doi.org/10.3109/13506129.2015.1135792.CrossRefPubMedGoogle Scholar
  21. 21.
    Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–62.  https://doi.org/10.1007/s00259-014-2787-6.CrossRefPubMedGoogle Scholar
  22. 22.
    Osborne DR, Acuff SN, Stuckey A, Wall JS. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir. Front Cardiovasc Med. 2015;2:23.  https://doi.org/10.3389/fcvm.2015.00023.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Broski SM, Spinner RJ, Howe BM, Dispenzieri A, Johnson GB. 18F-Florbetapir and 18F-FDG PET/CT in systemic immunoglobulin light chain amyloidosis involving the peripheral nerves. Clin Nucl Med. 2016;41:e115–7.  https://doi.org/10.1097/rlu.0000000000000947.CrossRefPubMedGoogle Scholar
  24. 24.
    García-González P, Sánchez-Jurado R, Cozar-Santiago MP, Ferrando-Beltrán M, Pérez-Rodriguez PL, Ferrer-Rebolleda J. Laryngeal and cardiac amyloidosis diagnosed by 18F-Florbetapir PET/CT. Rev Esp Med Nucl Imagen Mol. 2017;36:135–6.  https://doi.org/10.1016/j.remn.2016.03.006.PubMedGoogle Scholar
  25. 25.
    Leung N, Ramirez-Alvarado M, Nasr SH, Kemp BJ, Johnson GB. Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir. Br J Haematol. 2017;177:12.  https://doi.org/10.1111/bjh.14519.CrossRefPubMedGoogle Scholar
  26. 26.
    D'Estanque E, Chambert B, Moranne O, Kotzki PO, Boudousq V. 18F-Florbetaben: a new tool for amyloidosis staging? Clin Nucl Med. 2017;42:50–3.  https://doi.org/10.1097/rlu.0000000000001434.CrossRefPubMedGoogle Scholar
  27. 27.
    Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med. 1995;22:1393–401.CrossRefPubMedGoogle Scholar
  28. 28.
    Schaadt BK, Hendel HW, Gimsing P, Jonsson V, Pedersen H, Hesse B. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med. 2003;44:177–83.PubMedGoogle Scholar
  29. 29.
    Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med. 1995;22:595–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Bokhari S, Shahzad R, Castano A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21:175–84.  https://doi.org/10.1007/s12350-013-9803-2.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ohyama T, Shimokama T, Yoshikawa Y, Watanabe T. Splenic amyloidosis: correlations between chemical types of amyloid protein and morphological features. Mod Pathol. 1990;3:419–22.PubMedGoogle Scholar
  32. 32.
    Martins AC, Rosa AM, Costa E, Tavares C, Quadrado MJ, Murta JN. Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review. Biomed Res Int. 2015;2015:282405.  https://doi.org/10.1155/2015/282405.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Hachulla E, Janin A, Flipo RM, Saile R, Facon T, Bataille D, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum. 1993;36:691–7.CrossRefPubMedGoogle Scholar
  34. 34.
    de Paula EF, de Mello BL, de Carvalho DL, Della-Guardia B, de Almeida MD, Marins LV, et al. Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy. Neurol Sci. 2017;38:311–8.  https://doi.org/10.1007/s10072-016-2760-1.CrossRefGoogle Scholar
  35. 35.
    Villa F, Dionigi G, Tanda ML, Rovera F, Boni L. Amyloid goiter. Int J Surg. 2008;6(Suppl 1):S16–8.  https://doi.org/10.1016/j.ijsu.2008.12.025.CrossRefPubMedGoogle Scholar
  36. 36.
    Matsuda M, Gono T, Shimojima Y, Yoshida T, Katoh N, Hoshii Y, et al. AL amyloidosis manifesting as systemic lymphadenopathy. Amyloid. 2008;15:117–24.  https://doi.org/10.1080/13506120802006047.CrossRefPubMedGoogle Scholar
  37. 37.
    Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMedGoogle Scholar
  38. 38.
    Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53:403–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Medicine (Neurology and Rheumatology)Shinshu University School of MedicineNaganoJapan
  2. 2.Jisenkai Brain Imaging Research CenterMatsumotoJapan
  3. 3.Department of Biomedical Laboratory SciencesShinshu University School of Health SciencesMatsumotoJapan
  4. 4.Institute for Biomedical SciencesShinshu UniversityMatsumotoJapan

Personalised recommendations